EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuraminidase 1 secondary deficiency contributes to CNS pathology in neurological mucopolysaccharidoses via brain protein hypersialylation

TianMeng Xu, Rachel Heon-Roberts, Travis Moore, Patricia Dubot, Xuefang Pan, Tianlin Guo, Christopher W Cairo, Rebecca J Holley, Brian Bigger, Thomas M Durcan, Thierry Levade, Jerôme Ausseil und 12 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci177430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von TianMeng Xu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Neuraminidase, Brain, Mucopolysaccharidoses. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Canadian Institutes of Health Research, Vaincre Les Maladies Lysosomales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidoses (MPS) are lysosomal storage diseases caused by defects in catabolism of glycosaminoglycans. MPS I, II, III, and VII, which are associated with lysosomal accumulation of heparan sulphate (HS), manifest with neurological deterioration and currently lack effective treatments. We report that neuraminidase 1 (NEU1) activity is drastically reduced in brain tissues of patients with neurological MPS and mouse models but not in neurological lysosomal disorders without HS storage. Accumulated HS disrupts the lysosomal multienzyme complex of NEU1 with cathepsin A, β-galactosidase (GLB1), and glucosamine-6-sulfate sulfatase (GALNS), leading to NEU1 deficiency and partial GLB1 and GALNS deficiencies in cortical tissues and induced pluripotent stem cell–derived (iPSC-derived) cortical neurons of patients with neurological MPS. Increased sialylation of N-linked glycans in brains of patients with MPS and mice implicated insufficient processing of sialylated glycans, except for polysialic acid. Correction of NEU1 activity in MPS IIIC mice by lentiviral (LV) gene transfer ameliorated previously identified hallmarks of the disease, including memory impairment, behavioral traits, and reduced levels of excitatory synapse markers VGLUT1 and PSD95. Overexpression of NEU1 also restored levels of VGLUT1/PSD95–positive puncta in cortical iPSC-derived MPS IIIA neurons. Our results demonstrate that HS-induced secondary NEU1 deficiency and aberrant sialylation of brain glycoproteins constitute what we believe is a novel pathological pathway in the neurological MPS spectrum crucially contributing to CNS pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuraminidaseBrainMucopolysaccharidosesAnimalsHumansMiceInduced Pluripotent Stem CellsHeparan SulfateNeuronsMaleLysosomesFemaleMice, KnockoutMucolipidoses

Stichwörter der Autor:innen

Genetic diseasesGeneticsGlycobiologyLysosomesNeuroscience

Substanzen

NeuraminidaseHeparan SulfateNEU1 protein, humanNeu1 protein, mouse

Autor:innen und Institutionen

  • Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.
  • CHU Sainte-Justine Research Centre, Department of Paediatrics, University of Montreal, Montreal, Quebec, Canada.
  • Department of Neuroscience, Faculty of Science, McGill University, Quebec, Canada.
  • Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
  • Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom.
  • Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom.

Förderung

  • NIGMS NIH HHS
  • Canadian Institutes of Health Research
  • Vaincre Les Maladies Lysosomales
  • Sanfilippo Children’s Foundation
  • Canadian MPS Society for Mucopolysaccharide and Related Diseases
  • Canadian Glycomics Network

Zitieren

APA

Xu, T., Heon-Roberts, R., Moore, T., Dubot, P., Pan, X., Guo, T., Cairo, C. W., Holley, R. J., Bigger, B., Durcan, T. M., Levade, T., Ausseil, J., Amilhon, B., Gorelik, A., Nagar, B., Khan, S., Tomatsu, S., Sturiale, L., Palmigiano, A., …, & Pshezhetsky, A. V. (2025). Neuraminidase 1 secondary deficiency contributes to CNS pathology in neurological mucopolysaccharidoses via brain protein hypersialylation. Journal of Clinical Investigation. https://doi.org/10.1172/jci177430

Vancouver

Xu T, Heon-Roberts R, Moore T, Dubot P, Pan X, Guo T, et al. Neuraminidase 1 secondary deficiency contributes to CNS pathology in neurological mucopolysaccharidoses via brain protein hypersialylation. Journal of Clinical Investigation. 2025. doi:10.1172/jci177430

BibTeX
@article{Xu2025,
  author = {Xu, TianMeng and Heon-Roberts, Rachel and Moore, Travis and Dubot, Patricia and Pan, Xuefang and Guo, Tianlin and Cairo, Christopher W and Holley, Rebecca J and Bigger, Brian and Durcan, Thomas M and Levade, Thierry and Ausseil, Jerôme and Amilhon, Bénédicte and Gorelik, Alexei and Nagar, Bhushan and Khan, Shaukat and Tomatsu, Shunji and Sturiale, Luisa and Palmigiano, Angelo and Röckle, Iris and Thiesler, Hauke and Hildebrandt, Herbert and Garozzo, Domenico and Pshezhetsky, Alexey V},
  title = {Neuraminidase 1 secondary deficiency contributes to CNS pathology in neurological mucopolysaccharidoses via brain protein hypersialylation},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci177430}
}
Kostenlos starten →